Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371994 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy
A Phase 4 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 640
- Enrollment target
NCT01371994 is a Phase 4 study that has completed, run by Astellas Pharma. The registered enrollment target is 640 participants.
The verdict
NCT01371994, a Phase 4 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 640 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy. This study will also assess the effect of 12 weeks of treatment with solifenacin succinate versus placebo on quality of life (QOL) as measured by questionnaires.
Interventions
- DRUG Placebo
- DRUG solifenacin succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 640 participants |
| Start Date | 2011-08-02 |
| Est. Completion | 2013-10-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01371994
The ClinicalTrials.gov registry entry for NCT01371994 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 640 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01371994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01371994 about?
NCT01371994 is a clinical study titled "A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy". The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment of solifenacin succinate versus placebo in participants who are incontinent after Robotic Assisted Radical Prostatectomy. This study will also assess the effect of 12 weeks of treatment with solifenacin succinat...
What is the current status of trial NCT01371994?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 640 participants. The study started on 2011-08-02. Estimated completion is 2013-10-21.
What interventions are being tested in trial NCT01371994?
The interventions under investigation include: Placebo (DRUG), solifenacin succinate (DRUG).
Who is sponsoring clinical trial NCT01371994?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.